Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Global Blood Therapeutics Inc (NASDAQ: GBT) has announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study evaluating Oxbryta (voxelotor) tablets in patients with sickle cell disease (SCD). The results showed a significant and sustained improvement in hemoglobin levels, reduction in hemolysis, and improved overall health status, thus supporting the long-term use of Oxbryta.

Global Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease (SCD). The results showed significant and sustained improvement in hemoglobin levels, reduction in hemolysis and improved overall health status in patients treated with Oxbryta. These findings support the long-term use of Oxbryta to reduce hemolytic anemia and hemolysis in SCD, potentially mitigating life-threatening complications of the condition.

Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

Global Blood (GBT) Down 7.1% Since Last Earnings Report: Can It Rebound?

Sanofi

Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA (NASDAQ: SNY). One program pursues a novel anti-sickling mechanism, and the other leverages a new approach to reduce inflammation and oxidative stress.

GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease (SCD): one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress. These mechanisms are distinct and potentially complementary to that of Oxbryta® (voxelotor) tablets, a novel hemoglobin S polymerization inhibitor approved in the United States for the treatment of SCD in patients ages 12 years and older. The programs, from Sanofi's Bioverativ subsidiary, supplement GBT's existing pipeline and support the company's strategy to address SCD from multiple approaches.

GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.

Grant proposals from community-based organizations and institutions accepted through April 23, 2021 Grant proposals from community-based organizations and institutions accepted through April 23, 2021

GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community

SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) will participate at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021. A presentation by Ted W. Love, M.D., president and CEO of GBT, will be available at 7:00 a.m. ET.

GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2020 Results - Earnings Call Transcript

Expedia

Mattel

AT&T

Urban Outfitters

CME Group

Canadian Pacific Kansas City Limited

NetApp

SAGE Therapeutics

With the trading day more than halfway over, the broad markets saw a huge pull back on Thursday.

AT&T, Expedia, Mattel, Urban Outfitters and More Thursday Afternoon Analyst Calls

Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.

Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates

Shares of Global Blood Therapeutics (NASDAQ:GBT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 37.11% over the past year to ($1.00), which missed the estimate of ($0.94).

Recap: Global Blood Therapeutics Q4 Earnings

Achieved Oxbryta ® (voxelotor) net revenues of $41.3 million in the fourth quarter and  $123.8 million for full year 2020

GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

Global Blood Therapeutics (NASDAQ:GBT) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.

Preview: Global Blood Therapeutics's Earnings

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Global Blood Therapeutics (GBT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after U.S. financial markets close.

GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021

Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.

Global Blood's (GBT) MAA for Oxbryta Accepted in Europe

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation of GBT's Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) tablets and started its standard review process. GBT is seeking full marketing approval from the EMA for Oxbryta to treat hemolytic anemia in patients with sickle cell disease (SCD) who are 12 years of age and older.

European Medicines Agency Accepts GBT's Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease

Amphastar Pharma

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Colfax

Crh Medical

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

Lexicon Pharmaceuticals

MannKind

Nektar Therapeutics

Nano-X Imaging

ObsEva

Personalis Inc

PIMCO Corporate & Income Opportunity Fund

Construction Partners

Surgery Partners

SP Plus

Takeda Pharmaceutical

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

Global Blood Therapeutics ended 2020 with a nearly 40% drop in its share price. The pandemic negatively affected the number of Oxbryta prescriptions and therefore Oxbryta sales.

Global Blood Therapeutics: Ready To Face A Promising Year In 2021

Since 2017, GBT has come a long way to gain Oxbryta approval for treating sickle cell disease. After over 100% capital gains, the stock gave up some profits as the market is sizing up Oxbryta's sales prospects.

Global Blood Therapeutics: More Growth For Inclacumab

Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in F irst H alf of 2021

GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrat e Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status

GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition

Why Is Global Blood (GBT) Down 27.3% Since Last Earnings Report?

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States, for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older.

GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States

GBT has the only approved drug that can completely reverse sickle cell disease, which is affecting over 250k people worldwide. It has been subjected to an unwarranted selloff due to a slower than expected commercial launch despite the fact that this is likely a short-term impact due to COVID-19.

Global Blood Therapeutics: 40% Discount On A Billion-Dollar Drug

News for Global Blood Therapeutics Stock (GBT)